Washington, D.C. - The United States Postal Service announced in January 1999 that it will be printing an additional 80 million Breast Cancer Research Stamps due to the overwhelming success of this historic semi-postal fundraising stamp.
    Since it went on sale last summer, some 61 million stamps have been sold and The National Institutes of Health and Department of Defense Breast Cancer Research Program have already received $4.9 million from the funds raised by this stamp to date.

    This stamp is being issued as a two-year pilot and must meet certain criteria to extend beyond that time frame. You can make the difference.
    Please mail all your cards and letters with the stamp that will help your grandmothers, mothers, sisters, daughters, granddaughters and friends.
    Together we can "Fund the Fight. Find a Cure."

The Breast Cancer Research Semi-Postal Stamp is available at your local post office for $.40 each. The amount over the regular first class stamp rate will go directly to breast cancer research. 70% of the proceeds goes to the NIH and 30% goes to the DOD Breast Cancer Research Program.

To order by telephone, call the USPS at 1-800-Stamp24. Or visit: www.usps.com 

Los Angeles Coliseum / 5-8-99

    It's back and it's bigger and better than ever! The patter of little feet, big feet, slow feet and fast feet will all converge on the steps of the Los Angeles Coliseum to take part in the biggest event of its kind, theSixth Annual Revlon Run/Walk for Women. There will be mothers, daughters, sisters, fathers, sons, husbands, brothers and friends. People with big hearts come together to help run cancer into the ground. Join Event Host Dennis Franz, Revlon Spokeswomen Halle Berry, Kim Delaney, and San Francisco 49er, Steve Young.
Come join last year's 5th largest team in the race, the WIN ABC team #112. 
 

    Have you heard about the Her2/Neu gene that has changed the way that researchers have begun to understand and treat breast cancer? Dr. Dennis Slamon and the team at UCLA/Revlon Breast Center discovered "a successful cancer treatment that targets a specific genetic alteration."
    The new drug, Herceptin, was tested in clinical trials during the past 10 years It was found that approximately 30% of women who have breast cncer over express the Her2/Neu gene. In a large percentage of this group of women, Herceptin proved successful at stopping the growth of tumors in those struggling with metastatic breast cancer.
    Herceptin avoids the serious side effects associated with traditional chemotherapy. However, the trial results were more significant when using Herceptin in combination with other chemotherapy drugs.

    In May 1998, researchers at UCLA's Jonsson Cancer Center announced the positive results of the clinical trials. In September 1998, the FDA approved the drug for widespread use.
    At a special dinner held in Beverly Hills, on December 14, 1998, Dr. Slamon and the UCLA/Revlon Breast Center hosted a celebratory dinner at the Four Seasons Hotel in Beverly Hills. Dr. Slamon welcomed the attendees and thanked all the women who were the real heroines in the trials, as well as his fellow researchers and the many individuals who made the long journey in their fight against breast cancer to be present that night. Lilly Tartikoff, Co-Founder with Lisa Paulsen of the Revlon Run/Walk for Women, spoke and thanked Dennis Slamon for being a true hero.
    There is a new hope for patients who are fighting the battle against breast cancer. To see if you might benefit from this treatment, ask your doctor to have your tumor tested for the Her2/Neu gene.  
 

Amgen
Bristol-Myers Squibb
Coloplast
Nordstrom
Patton's
Schering-Plough Oncology